Your institution may have access to this item. Find your institution then sign in to continue.
Title
Santhera licenses novel dyskinesia therapy to Biovail.
Abstract
The article discusses the agreement between Biovail Laboratories Inc. and Santhera Pharmaceuticals Holding AG entitling Biovail the rights to develop and commercialize fipamezole also known as JP-1730 in Canada an U.S. It mentions that fipamezole is generated to treat levodopa-induced dyskinesia in parkinson's disease. It notes that Biovail paid Santhera eight million dollars for the rights.